Abstract:ID 95401 Poster Board 482 Objectives/Goals: Renal fibrosis is an outcome of chronic kidney disease that affects approximately one-tenth of the global community. Its pathogenesis and progression are highly multi-factorial, likely demanding a need to target various mechanisms for providing better treatment. Using an animal model of renal fibrosis, we sought to test the therapeutic response of TK-850, an experimental drug that acts as a dual-inhibitor of transforming growth factor beta receptor 1 (TGFβR1) and mitogen-activated protein kinase kinase kinase kinase 4 (MAP4K4). Both serine/threonine kinases are associated with inducing pro-inflammatory and pro-fibrotic responses. Methods/Study Population: To assess the possible renal anti-fibrotic effects of TK-850, we performed a preclinical study using 8-10-week-old male and female C57BL/6 mice, who underwent unilateral ureteral obstruction (UUO) surgery for inducing renal fibrosis. Rodents either had UUO only (control), were administered TK-850 prior to and following UUO (UUO-P, 20 mpk/d/ip), or administered TK-850 following UUO (UUO-I, 20 mpk/d/ip). In either case, the kidneys and blood were collected ten days post-UUO for histopathological evaluation and biochemical analysis. Fibrosis of the kidneys was evaluated from renal hydroxyproline estimation and Picrosirius red stain for assessing collagen deposition. Results/Anticipated Results (700-character limit): As a result of UUO, both male and female mice showed similar renal hydroxyproline levels, 5.4 ± 0.41 μg/10mg, n = 5 and 5.5 ± 0.50 μg/10mg, n = 5, respectively, in comparison to the contralateral (control) kidney, 2.9 ± 0.14 μg/10mg, n = 10. Prophylactic and interventional administration of TK-850 significantly reduced hydroxyproline levels (UUO-P: 3.4 ± 0.24 μg/10mg, n = 10; UUO-I: 4.30 ± 0.20 μg/10mg, n = 10). Histological assessment of kidney injury (UUO) revealed increased collagen deposition (17.1 ± 0.43% collagen positive area, n = 10) in comparison to the non-injured, control kidney (2.0 ± 0.23%, n = 10). TK-850 treatment was also shown to significantly reduce collagen deposition in UUO-P (10.5 ± 0.38%, n = 10) and UUO-I (13.1 ± 0.25%, n = 10) mice. Both biochemical and histological responses with and without drug treatment were gender neutral. Discussion/Significance of Impact (300-character limit): In summary, our results show a positive effect of TK-850 administration to reduce kidney injury, supporting the notion of its use as a potential therapeutic compound. The results herein could also affirm the idea of having a concerted pharmacotherapeutic approach to treat such complex diseases. Research reported in this abstract was supported by a Post-Doctoral TL1 Award from National Institutes of Health under grant numbers TL1 TR003109 and UL1 TR003107.

Renoprotection of Microcystin-RR in Unilateral Ureteral Obstruction-Induced Renal Fibrosis: Targeting the PKM2-HIF-1α Pathway

MiR-155-5p Promotes Renal Interstitial Fibrosis in Obstructive Nephropathy Via Inhibiting SIRT1 Signaling Pathway

Mitophagy Induced by UMI-77 Preserves Mitochondrial Fitness in Renal Tubular Epithelial Cells and Alleviates Renal Fibrosis

NMDA Receptor-mediated CaMKII/ERK Activation Contributes to Renal Fibrosis

Mefunidone Attenuates Tubulointerstitial Fibrosis in a Rat Model of Unilateral Ureteral Obstruction.

MK-2206 Alleviates Renal Fibrosis by Suppressing the Akt/mTOR Signaling Pathway In Vivo and In Vitro

Experimental Study of Mycophenolate Mofetil in Preventing Renal Interstitial Fibrosis in Rats

Fluorofenidone Inhibits UUO/IRI-Induced Renal Fibrosis by Reducing Mitochondrial Damage

Drp1-regulated PARK2-dependent Mitophagy Protects Against Renal Fibrosis in Unilateral Ureteral Obstruction

Genetic or Sirna Inhibition of MBD2 Attenuates the UUO- and I/R-induced Renal Fibrosis Via Downregulation of EGR1

MicroRNA-34a Promotes Renal Fibrosis by Downregulation of Klotho in Tubular Epithelial Cells

Resveratrol as a therapeutic agent for renal fibrosis induced by unilateral ureteral obstruction

Myeloid-Derived Suppressor Cells Alleviate Renal Fibrosis Progression <i>via</i> Regulation of CCL5-CCR5 Axis

A microRNA-30e|[sol]|mitochondrial uncoupling protein 2 axis mediates TGF-|[beta]|1-induced tubular epithelial cell extracellular matrix production and kidney fibrosis

MicroRNA-196a/b Mitigate Renal Fibrosis by Targeting TGF-β Receptor 2.

UCP1 alleviates renal interstitial fibrosis progression through oxidative stress pathway mediated by SIRT3 protein stability

Attenuation of renal injury by administration of TK-850, a dual inhibitor of TGF{beta}R1/MAP4K4

Cyclic Helix B Peptide Ameliorates Renal Tubulointerstitial Fibrosis Induced by Unilateral Ureter Obstruction Via Inhibiting NLRP3 Pathway.

Selective Inhibition of Class IIa Histone Deacetylases Alleviates Renal Fibrosis

Exogenous pancreatic kininogenase protects against renal fibrosis in rat model of unilateral ureteral obstruction